Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia
Hematological Oncology,Volume 36, Issue 1, Page 366-369, February 2018.
Source: Hematological Oncology - Category: Hematology Source Type: research
More News: Amyloidosis | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Rituxan